Virulizin immunomodulator: IMUTF (Toronto) said its planned Phase III trial of Virulizin would not take place until further study, perhaps in a Phase II trial,

IMUTEC Corp. (IMUTF)
Product: Virulizin immunomodulator
Indication:

Read the full 79 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE